Amplification of POLQ was associated with significantly worse prognosis in treatment-naïve prostate cancer [Fig. 4B; hazard ratio (HR) = 2.49; FDR = 7.78 × 10−3; confidence interval (CI) = 1.54–4.02]. The gene discussed is POLQ; the disease is Familial prostate cancer.